A Look into Angina Pectoris Drugs Industry……Deep Analysis…..
The global angina
pectoris drugs market is expected
to be valued at USD 10.6 Billion by 2022,
as per a new report by Grand View Research, Inc. The global angina pectoris
market is collectively driven by demand for disease-modifying and targeted
treatments, increased expenditure on healthcare and availability of effective
treatment methods across the emerging markets.
Multiple therapeutic regimens are being
followed across the globe in attempts to come up with a reliable treatment for
Covid-19. One line of treatment includes the use of hydroxychloroquine, while a
second treatment line focuses to use antiviral drugs used in the disease
management of HIV. Both these approaches have surged demand from advanced
antivirals and antimalarial drugs. This impacts the drug manufacturers as an
off label indication for these drug classes has to be worked upon. At the
moment, the WHO has not prescribed any of these approaches, neither they have
commented if one is better than the other. The report will account for Covid19
as a key market contributor.
Additionally, the rising prevalence
and incidence of angina pectoris is anticipated to fuel the market growth.
Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed
markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan.
The prevalence of angina pectoris rises sharply with age in both genders,
ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and
from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The
disease symptoms can be managed by following a healthy lifestyle.
The
global angina pectoris drugs market size was valued at USD 8.5 Billion in 2016
and is expected to grow at a CAGR of 3.2% during the forecast period. The U.S.
dominated angina pectoris drugs market among the seven major countries. The
global angina pectoris market is expected to be collectively driven by demand
for disease-modifying and targeted treatments, increased expenditure on
healthcare and availability of effective treatment methods across the emerging
markets.
To Request Sample Copy of this report, click the link:
Further key findings from the report
suggest:
·
The U.S. dominated this space
by accounting for more than 33.0% of the market share in 2016 due to increasing
incidence of cardiac disorders and presence of key manufacturers in the U.S.
·
The angina pectoris drug market
is commercially meaningful, however branded sales are in decline as generics
dominate a larger portion of prescriptions. Though the market is fragmented,
key players such as Sanofi, Gilead, AstraZeneca and Pfizer hold significant
market positions
·
Biosimilar development is
emerging as a promising market opportunity in angina pectoris therapeutics.
Multiple biosimilars have gained approvals in the U.S., European and Indian
markets
·
China offers strong opportunity
for market expansion due to removal of price caps on all medicine categories,
the ongoing Healthy China 2020 healthcare reform and supportive 12th Five-Year
Plan measure, which targets biotechnology as the key development sector
·
Changing regulatory scenario in
the U.S. presents favorable environment for disruptive technologies in
healthcare. In the EU, the new Clinical Trials Regulation (EU No. 536/2014)
will impact clinical trials of Advanced Therapy Medicinal Products. Industry
concerns regarding ROIs on novel therapies remains a challenge to drug
development.
Angina
pectoris is a clinical indication characterized by precordial heaviness or
discomfort due to transient myocardial ischemia without infarction, elicited by
physical exertion or psychological stress. Angina pectoris is categorized as -
stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an
initial presentation of coronary heart disease (CHD) and exerts a major impact
on quality of life (QOL), costs to the society and ability to work.
Chronic
stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major
markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and
Stroke Statistics from American Heart Association estimates indicate that over
nine million adults in the U.S. have chronic angina pectoris. We estimate
annual risk of associated non-fatal myocardial infarction (MI) and death at 3%
and 1.0-2.0% respectively. The prevalence of angina rises sharply with age in
both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men
aged 65-74 and from 0.1- 1.0% in women aged 45-54 to 10.0-15.0% in women aged
65-74.
Have any Query? Ask our Experts:
Grand View Research has segmented the
global angina pectoris drugs market based on therapeutic class:
Therapeutic Class Outlook (% market share; 2016 - 2022)
·
Beta Blockers
·
Calcium Antagonists
·
Anticoagulants
·
Anti-Platelets
·
Others
o Nitrates
o Anti-anginal (Ranolazine)
o ACE inhibitors
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment